The REVERT-PREDIABETES trial
Key facts
- Where
- Aarhus N, DániaSee the site
- Phase
- 4. fázis
Where in Dánia
- Region MidtjyllandAarhus N, DániaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Midtjylland
- Trial code
- EU 2025-522970-35-00
- Record updated
- 2025. november 23.
- Original description
To examine the proportion of patients with angiographically documented coronary artery disease that can be reverted from prediabetes to normoglycemia by using cardioprotective glucose-lowering drugs.Read full original descriptionShow less
REVERsal to normoglycemia by Treating PREDIABETES: the REVERT-PREDIABETES trial
To examine the proportion of patients with angiographically documented coronary artery disease that can be reverted from prediabetes to normoglycemia by using cardioprotective glucose-lowering drugs.
Inclusion: Chronic coronary syndrome with documented coronary artery disease. In the case of previous myocardial infarction, at least 30 days between the event and randomization is required; Prediabetes defined as HbA1c 42-47 mmol/mol OR normoglycemia defined as HbA1c <39 mmol/mol; Age 18 to 80 years.
Exclusion: Previous pancreatitis; Heart failure with NYHA class III or IV; Anemia, recent bleeding or blood transfusion (<3 months); Known hemoglobinopathy and other conditions with effect on erythrocyte lifespan; eGFR <30 mL/min/1.73 m2; Previous diabetes diagnosis, previous HbA1c >47 mmol/mol, or current/previous usage of diabetes medication; Intake of medications with known effect on HbA1c validity; Pregnancy, breastfeeding, or fertile women who do not use highly effective birth control; Strongly reduced liver function; Chronic alcohol abuse.